血清MG7-Ag测定法在卵巢癌患者诊断中的应用

Application of serum MG7-Ag determination in diagnosis of patients with ovarian cancer

目的:观察血清MG7-Ag测定在卵巢癌患者诊断中的临床价值。方法:选择卵巢恶性肿瘤组患者54例,卵巢良性肿瘤组患者67例,采用ELISA法检测全部患者血清中MG7-Ag的水平,并与同期进行体检的50例正常妇女(设为正常体检组)血清中MG7-Ag水平进行对照,对其结果进行比较。结果:卵巢恶性肿瘤组患者的MG7-Ag水平及阳性检出率均高于良性肿瘤组及正常妇女组,组间比较差异显著(P<0.05);而卵巢良性肿瘤组患者与正常妇女组相比,MG7-Ag的平均含量及阳性率均无显著性差异(P>0.05);黏液性肿瘤的MG7-Ag阳性表达率为57.14%(24/42),显著高于浆液性肿瘤31.03%(9/29)。结论:血清MG7-Ag测定对卵巢癌患者的诊断有特异性,可作为卵巢癌早期诊断的有效指标。

Objective:To investigate clinical value of serum MG7-Ag determination in diagnosis of ovarian cancer. Methods:54 patients with ovarian malignant tumor and 67 patients with benign ovarian tumor were selected. Serum MG7-Ag levels in all patients were detected by ELISA method. Meanwhile, 50 normal females underwent physical examination were included in this study, as the controls and their serum MG7-Ag levels were also detected. The detection results were compared. Results:The serum MG7-Ag level and positive rate in ovarian malignant tumor group were significantly higher than those in benign tumor group and normal control group (P<0. 05). There was no significant difference in the serum MG7-Ag level and positive rate between benign tumor group and normal control group (P>0. 05). The positive expression rate of MG7-Ag in mucinous tumor was 57. 14% (24/42), which was significantly higher than that in serous tumor (31. 03%, 9/29). Conclusions:Serum MG7-Ag level is a specific index for the diagnosis of ovarian cancer, and can be used as the effective index in early diagnosis of ovarian cancer.